Calendario›SNY›Cohort 1: Dupilumab · STRIDE

Cohort 1: Dupilumab · STRIDE

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

Ensayo de Sanofi en COPD (Chronic Obstructive Pulmonary Disease) (del registro, en inglés).

Fase

no aplica

Estado

Reclutando pacientes

Participantes

350

previstos

Centros

3

Fin del objetivo primario

jun 2029

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en ago 2026.

Qué mide

Participant Characteristics (End of study (24 months after the last participant is enrolled)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07612878), actualizada en ago 2026.